Report from the Annual General Meeting of EQL Pharma AB (publ) on August 27th, 2020
At EQL Pharma's Annual General Meeting, which was held in Lund, August 27th, 2020, the following decisions were made:
Adoption of the balance sheet and income statement, disposition regarding the Company’s results
The annual general meeting resolved to adopt the balance sheet and income statement and the consolidated balance sheet and income statement for the financial year 2019-04-01 – 2020-03-31. The annual general meeting also resolved that no dividends shall be paid for the financial year 2019/2020.
Discharge from liability for the Board of Directors and the Managing Director
The annual general meeting discharged the board members and the managing director from liability for the financial year 2019/2020.
Board of directors and auditor
The AGM resolved to re-elect Board members Christer Fåhraeus, Lars Holmqvist, Rajiv I Modi, Maria Bech and Anders Månsson as well as new election of Linda Neckmar. Ingemar Kihlström has declined re-election. It was decided to elect Anders Månsson as Chairman of the Board. Crowe Osborne AB was elected as auditing firm, with Olov Strömberg as auditor in charge.
The annual general meeting resolved that remuneration to the Board should be paid by SEK 250.000 to the Chairman of the Board and SEK 100.000 each to the remaining board members and that no Board fees shall be paid to Board members who are CEO. It was resolved that remuneration to the auditors shall be paid in accordance with approved invoices.
Resolution regarding principles for the appointment of a nomination committee, how members of the nomination committee are to be appointed and the tasks of the nomination committee
The annual general meeting resolved to adopt the principles proposed by the nomination committee for appointment of a nomination committee, how members of the nomination committee are to be appointed and the tasks of the nomination committee. The AGM's decision is in accordance with the proposal presented in the notice.
In conclusion, the Annual General Meeting thanked Ingemar Kihlström for his fantastic contribution during five years as chairman.
For further information, please contact:
CEO, EQL Pharma AB (publ)
Phone: +46 (0) 705 – 60 90 00
EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.